Time in therapeutic range (TTR) in anticoagulation clinic: Reports of adverse events and factors associated with low ttR

  • Harold Aníbal Miranda Rosero Clínica los Rosales, Pereira
  • Santiago Osorio Universidad de Antioquia
  • Diana Patricia Giraldo Méndez HUSVF
  • Julieta Duque Botero Universidad de Antioquia
  • John Ubéimar Cataño Hospital Universitario San Vicente Fundación
  • Luis Ignacio Tobón Universidad de Antioquia
  • Fernando Antonio Mejía Universidad de Antioquia
  • Felipe Gómez Isaza Universidad de Antioquia
  • Mario Bedoya Menco Universidad de Antioquia
  • Diana Carolina Inguilan Aguirre Universidad de Antioquia

Abstract

In the treatment of warfarin anticoagulation, reduction of thromboembolic events must be evaluated with the risk of bleeding. Time in therapeutic range (TTR) by the method of Rosendaal aluated with the risk of bleeding. Time in therapeutic range (TTR) by the method of Rosendaal is a tool that values quality monitoring anticoagulant therapy and correlates with the presence of thromboembolic events or bleeding. In this study time therapeutic range (TTR), factors associated with lower (TTR) and adverse effects presented in the anticoagulation clinic are presented. Methods and Results: A descriptive cross-sectional study from 1° January 2011 and 29th February 2012.2232 results of INR of 319 patients were assessed. 98550 days follow up. 44% (108) were men, 66% (211) women, average age 60.3 years, seven average visits / year, warfarin weekly dose of 29.8 mg. The weekly dose has an inverse relationship with age; in patients under 45 years 37.9 mg., and in patients over 75 years, 22.1 mg. The TTR increased from 48 to 54%, respectively. Indications for anticoagulation: atrial fibrillation (AF) 38% (121), venous thromboembolic disease (VTE) 35% (112), prosthetic valves (PV) 17.5% (56) and emboli or arterial thrombosis (EA) 9.5% (30). 228 patients (71%) had a TTR average of 64%. (40-100), INR greater than 5 in 2.24% and INR less than 1.5 in 10.9%. Minor bleeding: 16 patients (5%), major bleeding occurred in two patients (0.65%) and one adverse event of embolism (0.32%). The factors associated with low TTR were male gender, venous thromboembolic disease, use of generic warfarin, age less than 55 years, time shorter than one year and less than five visits. Conclusions: TTR is a useful measurement to establish the efficacy of anticoagulant therapy with warfarin. The goal of a 60% TTR ensures fewer adverse effects from bleeding or thrombosis. A low number of visits and anticoagulation less than a year are associated with low TTR.

Metrics

Metrics Loading ...

Author Biographies

Harold Aníbal Miranda Rosero, Clínica los Rosales, Pereira
Internista Vascular/ director Medico Diagnóstico Vascular / Pereira
Diana Patricia Giraldo Méndez, HUSVF
Internista. Medicina Vascular. Hospital Universitario San Vicente Fundación
John Ubéimar Cataño, Hospital Universitario San Vicente Fundación
Internista. Medicina Vascular.
Published
2016-06-23
How to Cite
Miranda Rosero, H. A., Osorio, S., Giraldo Méndez, D. P., Duque Botero, J., Cataño, J. U., Tobón, L. I., Mejía, F. A., Gómez Isaza, F., Bedoya Menco, M., & Inguilan Aguirre, D. C. (2016). Time in therapeutic range (TTR) in anticoagulation clinic: Reports of adverse events and factors associated with low ttR. Acta Medica Colombiana, 41(1), 42-48. https://doi.org/10.36104/amc.2016.524
Section
Original works